| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,522 |
2,404 |
$112K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
2,516 |
2,400 |
$83K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,735 |
1,634 |
$73K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,850 |
3,632 |
$69K |
| 80061 |
Lipid panel |
3,514 |
3,335 |
$67K |
| 80053 |
Comprehensive metabolic panel |
6,519 |
5,969 |
$63K |
| 80050 |
General health panel |
1,187 |
1,144 |
$56K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
1,527 |
1,448 |
$52K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
8,130 |
7,381 |
$51K |
| 87480 |
|
2,125 |
1,991 |
$48K |
| 87510 |
|
2,116 |
1,984 |
$40K |
| 87660 |
|
2,113 |
1,981 |
$40K |
| 36415 |
Collection of venous blood by venipuncture |
10,216 |
8,732 |
$38K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,384 |
1,314 |
$32K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
246 |
241 |
$32K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
4,056 |
3,633 |
$30K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,260 |
3,084 |
$24K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,481 |
1,418 |
$22K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
439 |
427 |
$22K |
| 87070 |
|
2,504 |
2,365 |
$21K |
| 82607 |
|
1,387 |
1,297 |
$19K |
| 81001 |
|
4,704 |
3,820 |
$14K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,683 |
1,528 |
$13K |
| 82728 |
|
1,108 |
1,055 |
$12K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
762 |
376 |
$12K |
| 84439 |
|
1,802 |
1,713 |
$11K |
| 81003 |
|
3,947 |
3,177 |
$8K |
| 87186 |
|
1,026 |
865 |
$8K |
| 80081 |
|
103 |
101 |
$8K |
| 86140 |
|
1,520 |
1,435 |
$7K |
| 87653 |
|
204 |
196 |
$7K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
87 |
84 |
$6K |
| 84481 |
|
525 |
506 |
$6K |
| 83550 |
|
948 |
915 |
$6K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
298 |
286 |
$5K |
| 83540 |
|
993 |
958 |
$5K |
| 81025 |
|
584 |
549 |
$5K |
| 86592 |
|
828 |
794 |
$3K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
16 |
15 |
$3K |
| 87147 |
|
422 |
332 |
$2K |
| 82950 |
|
436 |
413 |
$2K |
| 83735 |
|
372 |
324 |
$2K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
30 |
27 |
$2K |
| 86803 |
|
233 |
221 |
$2K |
| 82570 |
|
377 |
347 |
$2K |
| 84702 |
|
169 |
126 |
$1K |
| 87077 |
|
152 |
139 |
$1K |
| 87088 |
|
176 |
162 |
$1K |
| 85018 |
|
396 |
386 |
$1K |
| 83655 |
|
65 |
62 |
$832.87 |
| 82043 |
|
121 |
114 |
$635.26 |
| 86850 |
|
53 |
52 |
$520.39 |
| 85027 |
|
86 |
80 |
$427.07 |
| 87081 |
|
55 |
53 |
$385.01 |
| 87807 |
|
29 |
28 |
$351.62 |
| 87205 |
|
78 |
75 |
$331.70 |
| 84703 |
|
40 |
37 |
$318.17 |
| 82746 |
|
12 |
12 |
$260.70 |
| 83001 |
|
13 |
13 |
$245.35 |
| 85610 |
|
60 |
50 |
$189.68 |
| 87340 |
|
13 |
13 |
$155.54 |
| 85652 |
|
44 |
38 |
$122.85 |
| 83690 |
|
13 |
13 |
$75.79 |
| 80076 |
|
12 |
12 |
$73.53 |
| 85004 |
|
13 |
12 |
$14.36 |
| 86694 |
|
121 |
68 |
$13.50 |
| 82947 |
|
18 |
18 |
$13.11 |
| 86696 |
|
85 |
77 |
$9.08 |
| 86695 |
|
85 |
77 |
$6.19 |
| 85048 |
|
13 |
12 |
$5.64 |
| G0471 |
Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) |
88 |
72 |
$0.00 |